Silence Therapeutics plc (NASDAQ:SLN) Shares Sold by Barclays PLC

Barclays PLC lowered its stake in shares of Silence Therapeutics plc (NASDAQ:SLN) by 40.2% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 3,333 shares of the company’s stock after selling 2,237 shares during the period. Barclays PLC’s holdings in Silence Therapeutics were worth $61,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Y Intercept Hong Kong Ltd increased its stake in Silence Therapeutics by 22.9% during the 3rd quarter. Y Intercept Hong Kong Ltd now owns 21,078 shares of the company’s stock worth $383,000 after buying an additional 3,923 shares during the period. Point72 Asset Management L.P. raised its position in Silence Therapeutics by 219.3% in the 3rd quarter. Point72 Asset Management L.P. now owns 467,800 shares of the company’s stock valued at $8,505,000 after purchasing an additional 321,300 shares in the last quarter. Parkman Healthcare Partners LLC boosted its stake in shares of Silence Therapeutics by 71.8% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 497,870 shares of the company’s stock valued at $9,051,000 after buying an additional 208,029 shares during the period. Ikarian Capital LLC grew its position in shares of Silence Therapeutics by 15.9% during the third quarter. Ikarian Capital LLC now owns 587,343 shares of the company’s stock worth $10,678,000 after buying an additional 80,678 shares in the last quarter. Finally, Janus Henderson Group PLC grew its holdings in Silence Therapeutics by 32.8% during the 3rd quarter. Janus Henderson Group PLC now owns 1,087,228 shares of the company’s stock worth $19,798,000 after acquiring an additional 268,250 shares in the last quarter. Hedge funds and other institutional investors own 98.73% of the company’s stock.

Silence Therapeutics Price Performance

SLN stock opened at $6.34 on Friday. The company has a market cap of $189.74 million, a price-to-earnings ratio of -4.04 and a beta of 1.08. The company has a fifty day moving average price of $9.30 and a 200 day moving average price of $15.37. Silence Therapeutics plc has a 12 month low of $5.81 and a 12 month high of $27.72.

Wall Street Analysts Forecast Growth

SLN has been the topic of a number of analyst reports. HC Wainwright restated a “buy” rating and issued a $75.00 price target on shares of Silence Therapeutics in a research note on Monday, December 9th. William Blair reissued an “outperform” rating on shares of Silence Therapeutics in a research report on Tuesday, November 19th. BMO Capital Markets restated an “outperform” rating on shares of Silence Therapeutics in a research note on Monday, December 2nd. Morgan Stanley reiterated an “overweight” rating and issued a $49.00 price target on shares of Silence Therapeutics in a research note on Tuesday, October 8th. Finally, Chardan Capital restated a “buy” rating and issued a $55.00 target price on shares of Silence Therapeutics in a report on Tuesday, December 10th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $57.20.

Silence Therapeutics Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.